• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

灯盏花素通过HDAC/miR-34a介导的Akt/mTOR下调以及NF-κB协调的信号通路,规避化疗耐药性,促进细胞凋亡,并抑制多发性骨髓瘤中的肿瘤生长。

Scutellarin circumvents chemoresistance, promotes apoptosis, and represses tumor growth by HDAC/miR-34a-mediated down-modulation of Akt/mTOR and NF-κB-orchestrated signaling pathways in multiple myeloma.

作者信息

Li Lan, Zheng Yan, Zhang Weihua, Hou Limin, Gao Ying

机构信息

Department of Hematology, Shaanxi Provincial People's Hospital Xi'an 710068, Shaanxi, China.

出版信息

Int J Clin Exp Pathol. 2020 Feb 1;13(2):212-219. eCollection 2020.

PMID:32211101
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7061792/
Abstract

Multiple myeloma (MM) is a neoplastic dyscrasia of monoclonal immunoglobulin-secreting plasma cells culminating in multi-organ dysfunction. In this study, we sought to investigate whether scutellarin (STN), a flavonoid, could reduce MM progression, mitigate chemoresistance of MM cells to bortezomib (BTB), and cause MM cell apoptosis in a xenograft mouse model of MM. Epigenetic signalling plays a main role in the modulation of various pathways involved in multiple myeloma progression. At the outset, mechanistic analyses of the MM pathways indicated that key epigenetic molecules including HDAC1/3 and miR-34a were up-modulated and down-modulated respectively, in the MM mice. Besides, the downstream signalling analysis of miR-34a depicted that the c-Met/AKT/mTOR pathway was activated in the MM mice. We also investigated the expression of NF-κB, one of the major chemoresistance inducers in cancer treatment, in the MM mice. As anticipated, the tumor-bearing mice expressed more NF-κB along with elevated anti-apoptotic Bcl-xL protein, as well as reduced pro-apoptotic Bim protein. On the other hand, STN+BTB co-treatment effectively combated the MM tumor progression, and STN circumvented the MM tumor resistance to BTB and provoked apoptotic cell death in MM. Based on our study data, we deduce that STN, in combination with BTB, appears to be a reliable tumoricidal strategy.

摘要

多发性骨髓瘤(MM)是一种单克隆免疫球蛋白分泌浆细胞的肿瘤性血液疾病,最终导致多器官功能障碍。在本研究中,我们试图研究黄酮类化合物灯盏花素(STN)是否能在MM异种移植小鼠模型中减缓MM进展、减轻MM细胞对硼替佐米(BTB)的化疗耐药性并导致MM细胞凋亡。表观遗传信号在多发性骨髓瘤进展涉及的各种途径的调节中起主要作用。首先,对MM途径的机制分析表明,关键的表观遗传分子包括HDAC1/3和miR-34a在MM小鼠中分别上调和下调。此外,miR-34a的下游信号分析表明,c-Met/AKT/mTOR途径在MM小鼠中被激活。我们还研究了癌症治疗中主要化疗耐药诱导剂之一NF-κB在MM小鼠中的表达。正如预期的那样,荷瘤小鼠表达更多的NF-κB,同时抗凋亡Bcl-xL蛋白升高,促凋亡Bim蛋白减少。另一方面,STN+BTB联合治疗有效地对抗了MM肿瘤进展,STN克服了MM肿瘤对BTB的耐药性,并引发了MM细胞的凋亡性死亡。根据我们的研究数据,我们推断STN与BTB联合似乎是一种可靠的杀瘤策略。

相似文献

1
Scutellarin circumvents chemoresistance, promotes apoptosis, and represses tumor growth by HDAC/miR-34a-mediated down-modulation of Akt/mTOR and NF-κB-orchestrated signaling pathways in multiple myeloma.灯盏花素通过HDAC/miR-34a介导的Akt/mTOR下调以及NF-κB协调的信号通路,规避化疗耐药性,促进细胞凋亡,并抑制多发性骨髓瘤中的肿瘤生长。
Int J Clin Exp Pathol. 2020 Feb 1;13(2):212-219. eCollection 2020.
2
Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model.姜黄素在体外可克服化疗耐药性,并增强沙利度胺和硼替佐米对裸鼠模型中人类多发性骨髓瘤的治疗效果。
Mol Cancer Ther. 2009 Apr;8(4):959-70. doi: 10.1158/1535-7163.MCT-08-0905.
3
Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells.白藜芦醇通过下调信号转导和转录激活因子3(STAT3)以及核因子-κB调节的抗凋亡和细胞存活基因产物,抑制人多发性骨髓瘤细胞的增殖、诱导其凋亡并克服化疗耐药性。
Blood. 2007 Mar 15;109(6):2293-302. doi: 10.1182/blood-2006-02-003988. Epub 2006 Dec 12.
4
The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene.miR-34a-5p通过抑制AGTR1基因促进骨肉瘤的多药耐药性。
BMC Cancer. 2017 Jan 10;17(1):45. doi: 10.1186/s12885-016-3002-x.
5
Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.多发性骨髓瘤中 RASSF4 表达缺失促进 RAS 驱动的恶性进展。
Cancer Res. 2018 Mar 1;78(5):1155-1168. doi: 10.1158/0008-5472.CAN-17-1544. Epub 2017 Dec 19.
6
Mechanisms underlying synergism between circularized tumor necrosis factor-related apoptosis inducing ligand and bortezomib in bortezomib-sensitive or -resistant myeloma cells.环形肿瘤坏死因子相关凋亡诱导配体与硼替佐米协同作用在硼替佐米敏感或耐药骨髓瘤细胞中的机制。
Hematol Oncol. 2022 Dec;40(5):999-1008. doi: 10.1002/hon.3045. Epub 2022 Jul 14.
7
Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment.新型 miR-34a 为基础的治疗方法在多发性骨髓瘤治疗中的应用证据。
Sci Rep. 2017 Dec 20;7(1):17949. doi: 10.1038/s41598-017-18186-0.
8
MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.miR-34a 通过 PI3K/Akt/Bad 通路靶向 GAS1 促进甲状腺乳头状癌细胞增殖并抑制凋亡。
Biochem Biophys Res Commun. 2013 Nov 29;441(4):958-63. doi: 10.1016/j.bbrc.2013.11.010. Epub 2013 Nov 9.
9
MiRNA-34a overexpression inhibits multiple myeloma cancer stem cell growth in mice by suppressing TGIF2.微小RNA-34a过表达通过抑制TGIF2抑制小鼠多发性骨髓瘤癌干细胞生长。
Am J Transl Res. 2016 Dec 15;8(12):5433-5443. eCollection 2016.
10
Study on Tim3 Regulation of Multiple Myeloma Cell Proliferation NF-κB Signal Pathways.Tim3对多发性骨髓瘤细胞增殖的NF-κB信号通路调控的研究
Front Oncol. 2020 Nov 19;10:584530. doi: 10.3389/fonc.2020.584530. eCollection 2020.

引用本文的文献

1
Recent advancement in the anticancer efficacy of the natural flavonoid scutellarin: a comprehensive review.天然黄酮类化合物灯盏花素抗癌疗效的最新进展:综述
Front Pharmacol. 2025 Mar 27;16:1579609. doi: 10.3389/fphar.2025.1579609. eCollection 2025.
2
Scutellarin inhibits the glioma cell proliferation by downregulating BIRC5 to promote cell apoptosis.野黄芩苷通过下调 BIRC5 抑制神经胶质瘤细胞增殖,促进细胞凋亡。
J Cell Mol Med. 2023 Jul;27(14):1975-1987. doi: 10.1111/jcmm.17788. Epub 2023 Jun 20.
3
Synergistically Anti-Multiple Myeloma Effects: Flavonoid, Non-Flavonoid Polyphenols, and Bortezomib.黄酮类、非黄酮类多酚与硼替佐米协同抗多发性骨髓瘤作用
Biomolecules. 2022 Nov 7;12(11):1647. doi: 10.3390/biom12111647.
4
Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach.抑制蛋白精氨酸甲基转移酶PRMT5作为高危多发性骨髓瘤的一种新型治疗方法
Front Cell Dev Biol. 2022 Jun 8;10:879057. doi: 10.3389/fcell.2022.879057. eCollection 2022.
5
The HGF/c-MET axis as a potential target to overcome survival signals and improve therapeutic efficacy in multiple myeloma.HGF/c-MET轴作为克服生存信号并提高多发性骨髓瘤治疗疗效的潜在靶点。
Cancer Drug Resist. 2021 Oct 21;4(4):923-933. doi: 10.20517/cdr.2021.73. eCollection 2021.
6
Flavonoids as an effective sensitizer for anti-cancer therapy: insights into multi-faceted mechanisms and applicability towards individualized patient profiles.黄酮类化合物作为抗癌治疗的有效敏化剂:对多方面机制的见解以及对个体化患者情况的适用性。
EPMA J. 2021 May 17;12(2):155-176. doi: 10.1007/s13167-021-00242-5. eCollection 2021 Jun.
7
A New Twist in Protein Kinase B/Akt Signaling: Role of Altered Cancer Cell Metabolism in Akt-Mediated Therapy Resistance.蛋白激酶 B/Akt 信号的新转折:改变的癌细胞代谢在 Akt 介导的治疗抵抗中的作用。
Int J Mol Sci. 2020 Nov 13;21(22):8563. doi: 10.3390/ijms21228563.

本文引用的文献

1
miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1.miR-520g 和 miR-520h 通过抑制 APE1 克服多发性骨髓瘤中的硼替佐米耐药性。
Cell Cycle. 2019 Jul;18(14):1660-1669. doi: 10.1080/15384101.2019.1632138. Epub 2019 Jun 20.
2
Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling.靶向骨髓微环境中的组蛋白去乙酰化酶 3(HDAC3)通过调节外泌体和 IL-6 转导信号抑制多发性骨髓瘤增殖。
Leukemia. 2020 Jan;34(1):196-209. doi: 10.1038/s41375-019-0493-x. Epub 2019 May 29.
3
Long non-coding RNA ANGPTL1-3 promotes multiple myeloma bortezomib resistance by sponging miR-30a-3p to activate c-Maf expression.长非编码 RNA ANGPTL1-3 通过海绵吸附 miR-30a-3p 来激活 c-Maf 表达,从而促进多发性骨髓瘤硼替佐米耐药。
Biochem Biophys Res Commun. 2019 Jul 5;514(4):1140-1146. doi: 10.1016/j.bbrc.2019.05.078. Epub 2019 May 15.
4
miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma.miR-125b上调miR-34a并依次激活多发性骨髓瘤中的应激适应和细胞死亡机制。
Mol Ther Nucleic Acids. 2019 Jun 7;16:391-406. doi: 10.1016/j.omtn.2019.02.023. Epub 2019 Mar 13.
5
Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma.硼替佐米在复发或难治性多发性骨髓瘤患者真实临床环境中的治疗应用
Oncol Rev. 2019 Jan 18;13(1):377. doi: 10.4081/oncol.2019.377. eCollection 2019 Jan 14.
6
Scutellarin suppresses proliferation and promotes apoptosis in A549 lung adenocarcinoma cells via AKT/mTOR/4EBP1 and STAT3 pathways.野黄芩苷通过 AKT/mTOR/4EBP1 和 STAT3 通路抑制 A549 肺腺癌细胞的增殖并促进其凋亡。
Thorac Cancer. 2019 Mar;10(3):492-500. doi: 10.1111/1759-7714.12962. Epub 2019 Jan 21.
7
Mechanisms underlying the increased chemosensitivity of bortezomib-resistant multiple myeloma by silencing nuclear transcription factor Snail1.沉默核转录因子 Snail1 增加硼替佐米耐药多发性骨髓瘤的化疗敏感性的机制。
Oncol Rep. 2019 Jan;41(1):415-426. doi: 10.3892/or.2018.6797. Epub 2018 Oct 16.
8
Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016.多发性骨髓瘤全球负担:2016 年全球疾病负担研究的系统分析。
JAMA Oncol. 2018 Sep 1;4(9):1221-1227. doi: 10.1001/jamaoncol.2018.2128.
9
Nardilysin controls intestinal tumorigenesis through HDAC1/p53-dependent transcriptional regulation.内肽酶 Nardilysin 通过 HDAC1/p53 依赖性转录调控控制肠道肿瘤发生。
JCI Insight. 2018 Apr 19;3(8). doi: 10.1172/jci.insight.91316.
10
Scutellarin Increases Cisplatin-Induced Apoptosis and Autophagy to Overcome Cisplatin Resistance in Non-small Cell Lung Cancer via ERK/p53 and c-met/AKT Signaling Pathways.灯盏花素通过ERK/p53和c-met/AKT信号通路增强顺铂诱导的细胞凋亡和自噬,以克服非小细胞肺癌中的顺铂耐药性。
Front Pharmacol. 2018 Feb 13;9:92. doi: 10.3389/fphar.2018.00092. eCollection 2018.